Relationship between the amount of propranolol permeating through the stratum corneum of guinea pig skin after application of propranolol adhesive patches and skin irritation.
In the present study we evaluated the relationship between the cumulative amount of propranolol permeating through the stratum corneum and the formation of erythema, a skin irritation reaction, after transdermal application of adhesive patches containing propranolol to the skin of guinea pigs. The intensity of erythema was expressed in terms of a* values measured with a chromameter. The a* values increased in guinea pigs after application of the adhesive patches containing 0.4 mg/cm2 of propranolol to the skin. Since the adhesive patches showed good adhesion to the skin (propranolol content is less than the saturated concentration in the adhesive base) and the cumulative amount of propranolol permeating through the stratum corneum is small, the development of erythema was considered to be mainly due to physical factors such as peeling. Even in adhesive patches containing 0.8 mg/cm2 or 1.2 mg/cm2 of propranolol, a* values increased, although adhesion to the skin is low because of crystallization of propranolol in the adhesive base. On the other hand, in these two adhesive patches, the cumulative amount of propranolol permeating through the stratum corneum increased up to 24 h after application. These findings suggest that the skin irritation reaction is due to propranolol mainly absorbed transdermally, because there is a high correlation between the cumulative amount of propranolol permeating through the stratum corneum and the a* values (r = 0.928).
Kobayashi
I
I
Toxicological Research Center, Nitto Denko Corporation, Osaka, Japan.
Hosaka
K
K
Ueno
T
T
Maruo
H
H
Kamiyama
M
M
Konno
C
C
Gemba
M
M
D000279:Administration, Cutaneous; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000633:toxicity; D000818:Animals; D004817:Epidermis / Q000187:drug effects; D004890:Erythema / Q000139:chemically induced*; D006168:Guinea Pigs; D008297:Male; D011433:Propranolol / Q000008:administration & dosage* / Q000633:toxicity; D012867:Skin / Q000187:drug effects*; D012869:Skin Absorption
D000319:Adrenergic beta-Antagonists; D011433:Propranolol